Improving Treatment in Advanced Prostate Cancer ECHO

December 2024 - September 2025

Prostate cancer remains the second leading cause of cancer death in men in the U.S., with an estimated 35,250 deaths from prostate cancer expected in 2024 (American Cancer Society, 2024).  Advanced cancer treatment options can be complex, with varying risks and benefits, making shared decision-making a crucial part of treatment. 
The expertly designed curriculum of this ECHO program was developed to help address the challenges many oncologists and multidisciplinary team members face when providing care for patients with advanced prostate cancer.

Our Experts

This ECHO program is made possible through the generous support of Bayer Pharmaceuticals.